.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Novartis
Deloitte
Daiichi Sankyo
Fish and Richardson
Farmers Insurance
Express Scripts
Mallinckrodt
UBS
Chinese Patent Office

Generated: June 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,180,639

« Back to Dashboard

Summary for Patent: 6,180,639

Title: 1,3-oxathiolane nucleoside analogues
Abstract:(-)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, its pharmaceutically acceptable derivatives, pharmaceutical formulation thereof, methods for its preparation and its uses as an antiviral agent are described.
Inventor(s): Coates; Jonathan Allan (Greenford, GB), Mutton; Ian Martin (Greenford, GB), Penn; Charles Richard (Greenford, GB), Williamson; Christopher (Greenford, GB), Storer; Richard (Greenford, GB)
Assignee: BioChem Pharma Inc. (Laval, CA)
Application Number:07/835,964
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

No matches for this query

Foreign Priority and PCT Information for Patent: 6,180,639

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9009861May 02, 1990
PCT Information
PCT FiledMay 02, 1991PCT Application Number:PCT/GB91/00706
PCT Publication Date:November 14, 1991PCT Publication Number: WO91/17159

International Patent Family for Patent: 6,180,639

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO)182► Subscribe
African Regional IP Organization (ARIPO)9100255► Subscribe
Australia651345► Subscribe
Australia7771991► Subscribe
Bosnia and Herzegovina96098► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Citi
Accenture
Fuji
Covington
AstraZeneca
Cantor Fitzgerald
Novartis
Daiichi Sankyo
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot